CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-04-11 | Tucker Sean Chief Scientific Officer | Purchase · Common Stock Warrant (right to buy) | +27,273 | $1.10 | $30K | 27,273 |
| 2019-04-11 | Finney Michael J. Director | Purchase | +181,818 | $1.10 | $200K | 452,572 |
| 2019-04-11 | Finney Michael J. Director | Purchase · Common Stock Warrant | +181,818 | $1.10 | $200K | 181,818 |
| 2018-09-11 | Finney Michael J. Director | Other acquisition | +34,958 | 270,754 | ||
| 2018-09-11 | Harland John M Chief Financial Officer | Other acquisition | +761 | 761 | ||
| 2018-06-05 | Finney Michael J. Director | Purchase | +2,000 | $3.46 | $7K | 231,978 |
| 2018-06-05 | Finney Michael J. Director | Purchase | +65 | $2.91 | $189 | 232,043 |
| 2018-06-05 | Finney Michael J. Director | Purchase | +1,135 | $2.92 | $3K | 233,178 |
| 2018-06-05 | Finney Michael J. Director | Purchase | +800 | $2.91 | $2K | 233,978 |
| 2018-06-04 | Finney Michael J. Director | Purchase | +1,000 | $4.27 | $4K | 229,978 |
| 2018-05-25 | Harland John M Chief Financial Officer | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2018-05-25 | Latour Wouter President and Chief Executive | Grant or award · Stock Option (right to buy) | +110,700 | 110,700 | ||
| 2018-05-25 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +14,000 | 14,000 | ||
| 2018-03-12 | Tucker Sean Chief Scientific Officer | Option exercise | +2,013 | $6.49 | $13K | 47,653 |
| 2018-03-12 | Tucker Sean Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −2,013 | 0 | ||
| 2018-02-13 | Finney Michael J. Director | Grant or award | +1,818 | 230,796 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award | +45,640 | 45,640 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award | +9,060 | 9,060 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award | +25,388 | 25,388 | ||
| 2018-02-13 | Tucker Sean Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +2,014 | 2,014 |
Page 20 of 23 · 442 trades